Nick Wykeman and Manuel Llobet from Allergy Therapeutics plc (LON:AGY) caught up with Proactive Investors following the release of their interim results.
Allergy's continued to gain market share as it heads into a 'pivotal' twelve months.
Interim revenues rose by 4% to ?42.2mln despite the pollen season being described as 'abnormally weak'.
Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>